Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q1 FY22 results · Apr–Jun 2021
Astec LifeSciences reported revenue from operations of ₹128.66 crore (up 14.9% from Q1 FY21) and net profit of ₹12.99 crore (down 19.7% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 128.66 | 111.94 | +14.9% | 171.92 | −25.2% |
| Other income | 0.80 | 1.25 | −35.9% | 1.55 | −48.1% |
| Total income | 129.46 | 113.20 | +14.4% | 173.47 | −25.4% |
| Profit before tax | 17.44 | 21.74 | −19.8% | 32.18 | −45.8% |
| Net profit for the period | 12.99 | 16.19 | −19.7% | 23.97 | −45.8% |
| Attributable to shareholders of the company | 12.98 | 16.18 | −19.8% | 23.96 | −45.8% |
| EPS, basic (₹) | 6.63 | 8.27 | −19.8% | 12.24 | −45.8% |
| Net margin (%) | 10.1 | 14.5 | 13.9 |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 128.66 | 111.94 | +14.9% | 171.92 | −25.2% |
| Other income | 0.80 | 1.25 | −35.9% | 1.55 | −48.1% |
| Total income | 129.46 | 113.20 | +14.4% | 173.47 | −25.4% |
| Profit before tax | 17.42 | 21.72 | −19.8% | 32.15 | −45.8% |
| Net profit for the period | 12.97 | 16.17 | −19.8% | 23.94 | −45.8% |
| EPS, basic (₹) | 6.62 | 8.26 | −19.8% | 12.23 | −45.8% |
| Net margin (%) | 10.1 | 14.4 | 13.9 |
Consolidated
- Filed with BSE
- 29 Jul 2021, 14:22 IST
- Board meeting
- 28 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Jul 2021, 14:22 IST
- Board meeting
- 28 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE